Consensus Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse Other stock markets 04:00:02 2024-04-18 pm EDT			5-day change	1st Jan Change
48.3 ^USD	+0.96%		-1.67%	-5.87%

Apr. 18	Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating	MT
Apr. 17	TORL BioTherapeutics LLC announced that it has received $158.3 million in funding from a group of investors	CI

Evolution of the average Target Price on Bristol-Myers Squibb Company

Price target over the last 5 years

History of analyst recommendation changes

a61de6603d3cb34f3e01d6bc32.ud1hRwB5iMcZav1-4y0RIVKJINBbj0rSeh-yQbhCj5c.6bQxN3Es-IljJc841XJgDA24RL9qznuHNnr5HpUg29SBtCUhcjjZvVcYsA~10d35372b9424f1f5deb6c09db618c10

Analyst Recommendations on Bristol-Myers Squibb Company

Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating	Apr. 18	MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept	Apr. 15	MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating	Apr. 15	MT
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58	Apr. 12	MT
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating	Apr. 09	MT
Societe Generale Downgrades Bristol-Myers Squibb to Hold From Buy, Cuts Price Target to $51 From $85	Mar. 11	MT
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $51 From $58, Maintains Equalweight Rating	Feb. 06	MT
Redburn Downgrades Bristol-Myers Squibb to Neutral From Buy, Adjusts Price Target to $54 From $77	Feb. 06	MT
That's good enough for investors	Feb. 06
ANALYST RECOMMENDATIONS : Chevron, McDonald's, Palantir, Sainsbury, Tesla...	Feb. 06
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $41 From $42, Incorporates Mirati Transaction Into Model; Underweight Kept	Feb. 05	MT
UBS Cuts Bristol-Myers Squibb Price Target to $52 From $57, Maintains Neutral Rating	Jan. 17	MT
Berenberg: M&A Dealmaking in Pharmaceutical Sector to Further Accelerate in 2024	Jan. 09	MT
BofA Securities Downgrades Bristol-Myers Squibb to Neutral From Buy, Price Target is $60	Jan. 03	MT
Morgan Stanley Cuts Price Target on Bristol-Myers Squibb to $42 From $50, Keeps Underweight Rating	Dec. 12	MT
Are rate cuts are coming early next year?	Dec. 07
Joe Biden and Xi Jinping almost made up	Nov. 16
Cantor Fitzgerald Downgrades Bristol-Myers Squibb to Neutral From Overweight, Cuts Price Target to $55 From $68	Nov. 15	MT
Deutsche Bank Initiates Coverage on Bristol-Myers Squibb With Hold Rating, $55 Price Target	Nov. 09	MT
Daiwa Securities Downgrades Bristol-Myers Squibb to Neutral From Outperform, Adjusts Price Target to $54 From $68	Nov. 02	MT
Berenberg Bank Adjusts Bristol-Myers Squibb Price Target to $60 From $76, Maintains Hold Rating	Nov. 02	MT
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $69 From $81, Maintains Buy Rating	23-10-30	MT
North American Morning Briefing : Rate Decisions, -2-	23-10-30	DJ
UBS Adjusts Bristol-Myers Squibb Price Target to $57 From $60, Maintains Neutral Rating	23-10-27	MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $51 From $60, Maintains Equal-Weight Rating	23-10-27	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

48.3 USD

Average target price

56.33 USD

Spread / Average Target

+16.62%

High Price Target

75 USD

Spread / Highest target

+55.28%

Low Price Target

40 USD

Spread / Lowest Target

-17.18%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Bristol-Myers Squibb Company

Wells Fargo Securities
Wolfe Research
Jefferies & Co.
Morgan Stanley
Societe Generale
Redburn
UBS
BofA Securities
Cantor Fitzgerald
Deutsche Bank Securities
Daiwa Securities
Berenberg Bank
Goldman Sachs
Barclays
William Blair & Co.
BMO Capital
HSBC
TD Cowen
Credit Suisse
Atlantic Equities
Guggenheim
JPMorgan Chase
Raymond James
Citigroup
Truist Securities
Argus

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar